.jpg)
US pharmaceutical companies' trials of two different formulations of a combination vaccine for skin cancer (melanoma) have yielded encouraging results.
According to Reuters, an initial trial of a cancer vaccine developed by Moderna and Merck Insurance killed up to 44 percent of cancer patients. will go For the initial trial of this combination cancer vaccine, 34 patients with cancer tumors were examined and tested.
The experts found that the combined vaccines not only strengthened the immune system of skin cancer patients, but they also found that the vaccines helped the cells produce neoepitopes that kill the cancer cells. After producing the neoepitopes in the vaccinated patient, the said cells attack the cancer cells and thus the patient's disease is eradicated up to 44 percent.
The companies claimed that administering the combined vaccines intermittently after surgery to cancer patients led to a 44 percent reduction in disease. was made
It should be noted that the two companies signed an agreement to make a joint cancer vaccine in October this year.
Moderna's vaccine to help fight cancer is mRNA-4157, which makes T cells stronger, while Merck Insurance's vaccine is Keytruda, which kills cells that block the T-cell pathway. These companies have created a combined vaccine by combining the two different vaccines.
.jpg)
The experts found that the combined vaccines not only strengthened the immune system of skin cancer patients, but they also found that the vaccines helped the cells produce neoepitopes that kill the cancer cells. After producing the neoepitopes in the vaccinated patient, the said cells attack the cancer cells and thus the patient's disease is eradicated up to 44 percent.
The companies claimed that administering the combined vaccines intermittently after surgery to cancer patients led to a 44 percent reduction in disease. was made
It should be noted that the two companies signed an agreement to make a joint cancer vaccine in October this year.
Moderna's vaccine to help fight cancer is mRNA-4157, which makes T cells stronger, while Merck Insurance's vaccine is Keytruda, which kills cells that block the T-cell pathway. These companies have created a combined vaccine by combining the two different vaccines.
Comments
Post a Comment